CONSORT and Its Extensions for Reporting Clinical Trials

Sally Hopewell (), Isabelle Boutron () and David Moher ()
Additional contact information
Sally Hopewell: University of Oxford, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
Isabelle Boutron: Université de Paris, Epidemiology and Biostatistics Research Center (CRESS), Inserm UMR1153
David Moher: Centre for Journaology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canadian EQUATOR centre

Chapter 104 in Principles and Practice of Clinical Trials, 2022, pp 2073-2087 from Springer

Abstract: Abstract Well-designed and properly executed randomized controlled trials provide the most reliable evidence on the efficacy of healthcare interventions. However, there is overwhelming evidence that the quality of reporting of randomized trials is not always optimal. Without transparent reporting, readers cannot judge the reliability and validity of trial findings nor extract information for systematic reviews. Trials with inadequate methods are also associated with bias, especially exaggerated treatment effects (Savovic et al. 2012; Wood et al. 2008). Critical appraisal of the quality of clinical trials is only possible if the design, conduct, and analysis of randomized trials are thoroughly and accurately reported. The CONSORT (CONsolidated Standards of Reporting Trials) statement is comprised of a checklist of essential items that should be included in reports of randomized controlled trials and a diagram documenting the flow of participants through a trial. The objective of CONSORT is to provide guidance to authors about how to improve the reporting of their trials and ensure trial reports are clear, complete, and transparent (Moher et al. 2010a; Schulz et al. 2010a). Readers, peer reviewers, and editors can also use CONSORT to help them interpret the reports of randomized trials. CONSORT is not meant to be used as a quality assessment instrument, rather, the content of CONSORT relates to the internal and external validity of trials. Many items not explicitly mentioned in CONSORT may also be included in a report, such as information about approval by an ethics committee, informed consent from participants, and, where relevant, existence of a data and safety monitoring committee. The CONSORT statement thus addresses the minimum trial reporting criteria and should not deter authors from including other information they consider important (Moher et al. 2010a).

Keywords: CONSORT; Randomized controlled trial; Reporting guideline; Bias (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_188

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_188

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().